On May 8, 2025, Acurx Pharmaceuticals, Inc. entered into a purchase agreement with Lincoln Park Capital Fund for up to $12 million in common stock, allowing flexible sales over 24 months. Additionally, 899,258 shares were issued to Lincoln Park upon signing the agreement.